表紙
市場調查報告書

異位性皮膚炎 (AD):市場考察,流行病學,市場預測

Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 565327
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
異位性皮膚炎 (AD):市場考察,流行病學,市場預測 Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

本報告提供全球異位性皮膚炎 (AD)的市場相關分析,提供疾病概要和目前治療手法/演算法,新治療藥的開發·上市的動向,主要產品概要,全球整體及主要國家 (美國·歐洲各國·日本)的市場趨勢 (今後11年份),主要的推動及阻礙市場要素,目前未滿足需求,潛在的市場機會等相關調查。

第1章 簡介

第2章 異位性皮膚炎:市場概要

  • 市場佔有率結構 (最新值·預測值)

第3章 疾病的背景情況和概要

  • 病因
  • 風險要素
  • 病理生理學
  • 異位性皮膚炎 (AD)
    • AD伴隨的搔癢
    • 診斷方法

第4章 流行病學和患者人口

  • 疾病定義
  • 患者人口與預測參數
  • 患者人口的測量方法 (美國·歐洲·日本)
  • 異位性皮膚炎的患病人數: (7MM)主要7個國家
  • 異位性皮膚炎的患病人數:美國
  • 異位性皮膚炎的患病人數:德國
  • 異位性皮膚炎的患病人數:法國
  • 異位性皮膚炎的患病人數:義大利
  • 異位性皮膚炎的患病人數:西班牙
  • 異位性皮膚炎的患病人數:英國
  • 異位性皮膚炎的患病人數:日本
  • 異位性皮膚炎的患病人數:兒童 (重症度別), (7MM)主要7個國家
  • 異位性皮膚炎的患病人數:成人 (重症度別), (7MM)主要7個國家
  • 異位性皮膚炎的患病人數:發癢的程度, (7MM)主要7個國家
  • 異位性皮膚炎的患病人數:發癢的程度 (中度場合), (7MM)主要7個國家
  • 未治療的異位性皮膚炎的患病人數:主要7個國家 (7MM)
  • 未治療的異位性皮膚炎的患病人數:主要7個國家 (7MM),兒童/成人

第5章 治療手法

第6章 治療流程

  • 治療的目標
  • 全球各國的治療指南 (美國,日本,歐洲)

第7章 治療的失敗

  • 面向異位性皮膚炎已認證治療藥

第8章 新治療藥

第9章 Nemolizumab:Galderma Pharma

  • 產品概要
  • 研究開發 (R&D)
  • 產品開發的動向

第10章 Tralokinumab:LEO Pharma

第11章 Tradipitant:Vanda Pharmaceuticals

第12章 ZPL-389:Novartis

第13章 NST-141:日本新藥

第14章 Serlopitant:Menlo Therapeutics

第15章 DS107:DS Biopharma

第16章 Asimadoline:Tioga Pharmaceuticals

第17章 GSK2894512:GlaxoSmithKline

第18章 Lebrikizumab:Roche

第19章 DMT210:Dermata Therapeutics

第20章 RVT-501:Roivant Sciences

第21章 OPA-15406:大塚製藥

第22章 現狀的未滿足需求

第23章 異位性皮膚炎:市場分析

  • 市場未來展望: (7MM)主要7個國家
  • (7MM)主要7個國家的異位性皮膚炎的市場規模

第24章 異位性皮膚炎:美國市場的展望

  • 美國的市場規模

第25章 異位性皮膚炎:歐洲市場展望

  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模

第26章 異位性皮膚炎:日本市場展望

  • 日本的市場規模

第27章 推動市場要素

第28章 阻礙市場要素

第29章 專家的見解

第30章 目前治療選擇的見解

第31章 新治療藥相關見解

第32章 附錄

第33章 分析方法

  • 利用之資訊來源

第34章 DelveInsight的服務內容

第35章 免責聲明

第36章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0253

DelveInsight's "Atopic Dermatitis (AD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atopic Dermatitis (AD) market report provides current treatment practices, emerging drugs, Atopic Dermatitis (AD) market share of the individual therapies, current and forecasted Atopic Dermatitis (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Atopic Dermatitis (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Atopic Dermatitis (AD) Disease Understanding and Treatment Algorithm

The DelveInsight Atopic Dermatitis (AD) market report gives a thorough understanding of the Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Atopic Dermatitis (AD).

Treatment

It covers the details of conventional and current medical therapies available in the Atopic Dermatitis (AD) market for the treatment of the condition. It also provides Atopic Dermatitis (AD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Atopic Dermatitis (AD) Epidemiology

The Atopic Dermatitis (AD) epidemiology division provide insights about historical and current Atopic Dermatitis (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Atopic Dermatitis (AD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Atopic Dermatitis (AD) Epidemiology

The epidemiology segment also provides the Atopic Dermatitis (AD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Atopic Dermatitis (AD) Drug Chapters

Drug chapter segment of the Atopic Dermatitis (AD) report encloses the detailed analysis of Atopic Dermatitis (AD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atopic Dermatitis (AD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Atopic Dermatitis (AD) treatment.

Atopic Dermatitis (AD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Atopic Dermatitis (AD) treatment.

Atopic Dermatitis (AD) Market Outlook

The Atopic Dermatitis (AD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Atopic Dermatitis (AD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Atopic Dermatitis (AD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Atopic Dermatitis (AD) market in 7MM.

The United States Market Outlook

This section provides the total Atopic Dermatitis (AD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Atopic Dermatitis (AD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Atopic Dermatitis (AD) market size and market size by therapies in Japan is also mentioned.

Atopic Dermatitis (AD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis (AD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Atopic Dermatitis (AD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Dermatitis (AD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Atopic Dermatitis (AD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Atopic Dermatitis (AD) emerging therapies.

Reimbursement Scenario in Atopic Dermatitis (AD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Atopic Dermatitis (AD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Atopic Dermatitis (AD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Atopic Dermatitis (AD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Atopic Dermatitis (AD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Atopic Dermatitis (AD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atopic Dermatitis (AD) market

Report Highlights

  • In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Atopic Dermatitis (AD). Launch of emerging therapies will significantly impact the Atopic Dermatitis (AD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atopic Dermatitis (AD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Atopic Dermatitis (AD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Atopic Dermatitis (AD) Pipeline Analysis
  • Atopic Dermatitis (AD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Atopic Dermatitis (AD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Atopic Dermatitis (AD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Atopic Dermatitis (AD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Atopic Dermatitis (AD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Atopic Dermatitis (AD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Atopic Dermatitis (AD) market size during the forecast period (2017-2030)?
  • At what CAGR, the Atopic Dermatitis (AD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Atopic Dermatitis (AD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Atopic Dermatitis (AD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Atopic Dermatitis (AD)?
  • What is the historical Atopic Dermatitis (AD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Atopic Dermatitis (AD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Atopic Dermatitis (AD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Atopic Dermatitis (AD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Atopic Dermatitis (AD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Atopic Dermatitis (AD) in the USA, Europe, and Japan?
  • What are the Atopic Dermatitis (AD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Atopic Dermatitis (AD)?
  • How many therapies are developed by each company for Atopic Dermatitis (AD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Atopic Dermatitis (AD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis (AD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atopic Dermatitis (AD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Atopic Dermatitis (AD)?
  • What are the global historical and forecasted market of Atopic Dermatitis (AD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Atopic Dermatitis (AD) market
  • To understand the future market competition in the Atopic Dermatitis (AD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) market
  • To understand the future market competition in the Atopic Dermatitis (AD) market

Table of Contents

1. Key Insights

2. Executive Summary of Atopic Dermatitis (AD)

3. Competitive Intelligence Analysis for Atopic Dermatitis (AD)

4. Atopic Dermatitis (AD): Market Overview at a Glance

  • 4.1. Atopic Dermatitis (AD) Total Market Share (%) Distribution in 2017
  • 4.2. Atopic Dermatitis (AD) Total Market Share (%) Distribution in 2030

5. Atopic Dermatitis (AD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Atopic Dermatitis (AD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Atopic Dermatitis (AD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Atopic Dermatitis (AD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Atopic Dermatitis (AD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Atopic Dermatitis (AD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Atopic Dermatitis (AD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Atopic Dermatitis (AD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Atopic Dermatitis (AD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Atopic Dermatitis (AD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Atopic Dermatitis (AD) Treatment and Management
  • 8.2. Atopic Dermatitis (AD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Atopic Dermatitis (AD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Atopic Dermatitis (AD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Atopic Dermatitis (AD) Market Size in 7MM
  • 13.3. Atopic Dermatitis (AD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Atopic Dermatitis (AD) Total Market Size in the United States
    • 15.1.2. Atopic Dermatitis (AD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Atopic Dermatitis (AD) Total Market Size in Germany
    • 15.3.2. Atopic Dermatitis (AD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Atopic Dermatitis (AD) Total Market Size in France
    • 15.4.2. Atopic Dermatitis (AD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Atopic Dermatitis (AD) Total Market Size in Italy
    • 15.5.2. Atopic Dermatitis (AD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Atopic Dermatitis (AD) Total Market Size in Spain
    • 15.6.2. Atopic Dermatitis (AD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Atopic Dermatitis (AD) Total Market Size in the United Kingdom
    • 15.7.2. Atopic Dermatitis (AD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Atopic Dermatitis (AD) Total Market Size in Japan
    • 15.8.3. Atopic Dermatitis (AD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Atopic Dermatitis (AD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Atopic Dermatitis (AD) Epidemiology (2017-2030)
  • Table 2 : 7MM Atopic Dermatitis (AD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Atopic Dermatitis (AD) Epidemiology in Germany (2017-2030)
  • Table 6 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Atopic Dermatitis (AD) Epidemiology in France (2017-2030)
  • Table 8 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Atopic Dermatitis (AD) Epidemiology in Italy (2017-2030)
  • Table 10 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Atopic Dermatitis (AD) Epidemiology in Spain (2017-2030)
  • Table 12 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Atopic Dermatitis (AD) Epidemiology in the UK (2017-2030)
  • Table 14 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Atopic Dermatitis (AD) Epidemiology in Japan (2017-2030)
  • Table 16 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Atopic Dermatitis (AD) Epidemiology (2017-2030)
  • Figure 2 : 7MM Atopic Dermatitis (AD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Atopic Dermatitis (AD) Epidemiology in the United States (2017-2030)
  • Figure 4 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Atopic Dermatitis (AD) Epidemiology in Germany (2017-2030)
  • Figure 6 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Atopic Dermatitis (AD) Epidemiology in France (2017-2030)
  • Figure 8 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Atopic Dermatitis (AD) Epidemiology in Italy (2017-2030)
  • Figure 10 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Atopic Dermatitis (AD) Epidemiology in Spain (2017-2030)
  • Figure 12 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Atopic Dermatitis (AD) Epidemiology in the UK (2017-2030)
  • Figure 14 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Atopic Dermatitis (AD) Epidemiology in Japan (2017-2030)
  • Figure 16 : Atopic Dermatitis (AD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)